On January 28, 2020, HRSA posted results
of its 340B Program audit of four pharmaceutical manufacturers in fiscal year 2019. Three of the four
audited manufacturers were
On January
27, 2020, the U.S. Government Accountability Office (GAO) released a report (the Report) assessing oversight
by the Department of Health and Human Services (HHS) of
On January 17, 2020, the Medicare Payment Advisory
Commission (MedPAC) held its first meeting of the year, including a session
discussing a report requested by the House
On January
10, 2020, the U.S. Government Accountability Office (GAO) released a report
(the Report) analyzing HRSA’s oversight of 340B eligibility requirements for
nongovernmental hospitals. The Report concludes
HRSA announced that it has awarded Apexus LLC the prime vendor contract again after a competitive bid process. Apexus has been the 340B Prime Vendor
On January
8, 2020, the Centers for Medicare & Medicaid Services (CMS) issued an Informational Bulletin (Bulletin) outlining CMS’s view of
current “best practices” by states to
The federal appeals court for the District of Columbia
Circuit recently ruled in favor of the Humana Medicare Advantage plan in a case
by a 340B covered
Last week, Apexus published a tool which states for the first time HRSA’s policy that all non-FQHC federal grantees are required to register each of
340B Health reports that Capt. Krista Pedley, the Director of OPA, stated last week at the Medicaid Drug Rebate Conference that OPA is reevaluating its
In a Federal Register notice issued yesterday, CMS announced that it intends to survey hospitals on their acquisition costs for covered outpatient drugs purchased under the 340B
